Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.41 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2429949 | 0.79 | — | — | |
| SCHEMBL19501243 | 0.77 | GNAI3 (0.55) | DRD2PABPC1GNAI3GNAO1GNAI1 | |
| SCHEMBL1290932 | 0.77 | CARM1 (0.58) | DRD2 | |
| SCHEMBL9925579 | 0.77 | DRD2 (0.48) | DRD2PABPC1GNAI3GNAO1GNAI1 | |
| SCHEMBL5471689 | 0.77 | DRD2 (0.48) | DRD2GNAI3GNAO1GNAI1SLC6A4 | |
| SCHEMBL1540648 | 0.76 | DRD2 (0.44) | DRD2GNAI3GNAO1GNAI1SLC6A4 | |
| SCHEMBL8324635 | 0.75 | DRD2 (0.47) | DRD2PABPC1GNAI3GNAO1GNAI1 | |
| SCHEMBL19605702 | 0.75 | DRD2 (0.47) | DRD2PABPC1GNAI3GNAO1GNAI1 | |
| SCHEMBL10076885 | 0.75 | DRD2 (0.47) | DRD2GNAI3GNAO1GNAI1SLC6A4 | |
| SCHEMBL7220679 | 0.75 | GNAI3 (0.67) | DRD2PABPC1GNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2539342-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | Mitsubishi Tanabe Pharma Corporation (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-12-06 | — | — | US | disclosed |
| US-8173659-B2 | Substituted pyrazolo[4,3-C]pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-05-08 | — | — | US | disclosed |
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-09-22 | — | — | US | disclosed |
| WO-2011105628-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-09-01 | — | — | WO | disclosed |
| US-7947686-B2 | Substituted pyrazolo[4,3-c]pyridine derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-24 | — | — | US | disclosed |
| US-20090023745-A1 | Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230470-A1 | SUBSTITUTED PYRAZOLO[4,3-C]PYRIDINE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K3, MAP3K1, MAP3K19 | DRD2 4863/4885PABPC1 1460/4885GNAI3 536/4885 |
| US-20120309754-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS | PDE3B, PDE3A, PDE5A | DRD2 1459/4885PABPC1 1779/4885GNAI3 906/4885 |
| US-20090023745-A1 | Substituted Pyrazolo[4,3-c]Pyridine Derivatives Active as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K19 | DRD2 4863/4885PABPC1 1460/4885GNAI3 536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.